Brickell Biotech Stock

Brickell Biotech Net Margin

Delisted

The Net Profit Margin of Brickell Biotech (BBI) as of Aug 5, 2026 is -303.93 %. In the previous year, Net Profit Margin was -9,787.87 % — a change of -96.89% (higher).

Net Margin

-303.93 %

YoY

-96.89%

Last updated:

Net Profit Margin of Brickell Biotech is 2026 -303.93 % . Net Profit Margin of Brickell Biotech was 2025 -9,787.87 % . It decreases by -96.89% higher compared to the previous year.

Brickell Biotech's net margin stands at -303.9%, up from -1,002.1% several years earlier.

Access this data via the Eulerpool API

Brickell Biotech Stock analysis

What does Brickell Biotech do? Brickell Biotech Inc is a biopharmaceutical company that focuses on the development and marketing of innovative dermatology products. The company was founded in 2009 and is headquartered in Boulder, Colorado (USA), with branches in California and Singapore. The history of Brickell Biotech dates back to the 1960s when the company was originally founded under the name Brickell Research Inc. Over the following decades, the company specialized in biological research and conducted important research that forms the basis for today's product development. Brickell Biotech's business model is based on the creation of new and innovative therapies for the treatment of various dermatological diseases. In recent years, the company has entered into a number of important partnerships to accelerate its product development and strengthen its position in the industry. Brickell Biotech operates in two main areas: pharmaceuticals and cosmetic products. In the pharmaceuticals area, the company has a number of promising therapies in the pipeline that target the treatment of skin cancer, psoriasis, and other dermatological conditions. The company's flagship product is Sofpironium Bromide, a potential treatment for hyperhidrosis (excessive sweating). In the cosmetic products area, the company has developed a range of skincare products tailored to the needs of people with sensitive, dry, or aging skin. These products include moisturizers, cleansers, and anti-aging products, all made from high-quality ingredients. Brickell Biotech works closely with the scientific community to explore the latest developments and innovations in dermatology and the cosmetics industry. The company has also established a strong presence in the medical and research sectors by collaborating closely with leading universities and medical institutions worldwide. Overall, Brickell Biotech is a promising company in the biopharmaceutical and cosmetics industry, specializing in the development of new and innovative therapies for the treatment of skin conditions. With a strong pipeline of products and a dedicated leadership team, the company is expected to continue growing and establish itself as an important player in the industry. Brickell Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brickell Biotech stock

Net Profit Margin of Brickell Biotech is -303.93 % in 2026.

Net Profit Margin of Brickell Biotech changed from -9,787.87 % to -303.93 %, representing a -96.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Brickell Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Brickell Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Brickell Biotech

All Key Metrics — Brickell Biotech